3De Stefano V, Martinelli I, Leone G, et al. The risk of recur- rent deep venous thrombosis among heterozygous carriers of both factorV Leiden and the G20210A prothrombin mutation [J]. N Engl J Med, 1999, 341(11): 801-806.
4Gerhardt A, Seharf RE, Beckmarm MW, et aL Prothrombin and factor V mutations in women with a history of thrombosis dur- ing pregnancy and the puerperium [ J ]. N Engl J Med, 2000, 342(6): 374-380.
5Bertina RM, Koelemen BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C [J]. Nature, 1994, 369(6475): 64-67.
6Rees DC, Cox M, Clegg JB, et aL World distribution of factor V Leiden [J]. Lancet, 1995, 346(8983): 1133-1134.
8Mazoyer E, Ripoll L, Gueguen R, et al. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution [J]. Blood Coagul Fibrinolysis, 2009, 20(7): 503-510.
9Agrawal N, Kurnar S, Puneet, et al. Activated protein C resist- ance in deep venous thrombosis [J]. Ann Vase Surg, 2009, 23(3): 364-366.
10MIDDENDORF K, GOHRING P, HUEHNS T Y, et al. Prevalence of resistance against activated protein C resul- ting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction[J]. Am Heart J, 2004, 147 (5): 897 -904.
